hsa-miR-9

ncRNA information

ncRNA name

hsa-miR-9

Specific or universal ncRNAs

Universal ncRNAs

Class

MicroRNA

Biomarker

Yes

Biomarker application

Treatment

Upstream regulatory factors

Not available

Downstream target

ABCB1

Cancer information

Cancer name

Chronic Myelogenous Leukemia

Cancer site

Leukemia

Treatment information

Treatment type

Chemotherapy

Drug

Doxorubicin/Paclitaxel/Vincristine

Impact of wild-type ncRNA on chemotherapy resistance

Impact of knockdown of ncRNA on chemotherapy resistance

Impact of overexpression of ncRNA on chemotherapy resistance

Down

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Not available

Number of patients

61

Male patients

38

Female patients

23

Age range and number

Not available

Research information

PMID

Description

Overexpression of miR-9 was sufficient to reverse cancer cell resistance to multiple chemotherapeutics in vitro and sensitized tumors to chemotherapy in vivo.

Tissue resource

peripheral blood from chronic myeloid leukemia patients

human chronic myelogenous leukemia cell lines K562

Experiment

qRT-PCR,Western blot,Luciferase reporter assay


Institute

the First Affiliated Hospital of Dalian Medical University

Country

China

Continent

Asia